BioCentury
ARTICLE | Product R&D

Sweet specificity

Siamab’s sugar-targeted mAbs yield a lead program and Boehringer deal

November 2, 2017 5:50 PM UTC

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal with Boehringer and a pathway to companion diagnostics.

The biotech is now disclosing the first fruits of its platform, with three presentations in the last month on ST1 ADC, an antibody-drug conjugate (ADC) in preclinical testing for solid tumors, slated to enter the clinic in 2019. ...